Roivant Sciences Ltd. (NASDAQ:ROIV) Shares Sold by Rhumbline Advisers

Rhumbline Advisers cut its stake in Roivant Sciences Ltd. (NASDAQ:ROIV) by 1.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,075,091 shares of the company’s stock after selling 11,498 shares during the quarter. Rhumbline Advisers owned approximately 0.15% of Roivant Sciences worth $12,718,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in ROIV. New Mexico Educational Retirement Board increased its position in shares of Roivant Sciences by 28.4% during the fourth quarter. New Mexico Educational Retirement Board now owns 88,970 shares of the company’s stock worth $1,053,000 after purchasing an additional 19,670 shares in the last quarter. New York State Teachers Retirement System grew its holdings in shares of Roivant Sciences by 2.0% during the 4th quarter. New York State Teachers Retirement System now owns 254,220 shares of the company’s stock worth $3,007,000 after purchasing an additional 4,959 shares during the period. Elevate Capital Advisors LLC acquired a new position in Roivant Sciences during the 4th quarter worth about $2,116,000. China Universal Asset Management Co. Ltd. lifted its stake in Roivant Sciences by 8.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 154,352 shares of the company’s stock worth $1,826,000 after acquiring an additional 12,118 shares in the last quarter. Finally, FSA Advisors Inc. acquired a new stake in Roivant Sciences in the 4th quarter valued at about $130,000. 64.76% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the company’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $11.49, for a total transaction of $1,149,000.00. Following the completion of the sale, the chief operating officer now directly owns 595,580 shares in the company, valued at $6,843,214.20. This represents a 14.38 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CIO Mayukh Sukhatme sold 185,946 shares of the company’s stock in a transaction dated Tuesday, December 24th. The stock was sold at an average price of $12.00, for a total value of $2,231,352.00. Following the sale, the executive now owns 18,836,547 shares of the company’s stock, valued at $226,038,564. This represents a 0.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 2,288,170 shares of company stock worth $26,547,299 over the last three months. 7.90% of the stock is currently owned by corporate insiders.

Roivant Sciences Stock Performance

ROIV opened at $10.68 on Friday. The business’s fifty day moving average is $11.21 and its two-hundred day moving average is $11.59. The company has a market cap of $7.62 billion, a price-to-earnings ratio of -71.20 and a beta of 1.25. Roivant Sciences Ltd. has a one year low of $9.76 and a one year high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last posted its earnings results on Monday, February 10th. The company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. On average, analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a research report on Thursday, January 30th. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Roivant Sciences in a research note on Tuesday, February 11th. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $18.08.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.